Oncology Institute, Inc. (TOIIW)
2025-06-30 | ||||
|---|---|---|---|---|
| Total operating revenue | 119,802 | |||
| Selling, general and administrative expense | 26,907 | |||
| Depreciation and amortization | 1,805 | |||
| Direct costs-Health Care Patient Service | 51,150 | |||
| Direct costs-Dispensary Revenue | 51,086 | |||
| Direct costs-Clinical Research Trials And Other Revenue | 65 | |||
| Total operating expenses | 131,013 | |||
| Loss from operations | -11,211 | |||
| Other, net | -19 | |||
| Interest expense, net | 1,870 | |||
| Change in fair value of derivative warrant liabilities | 53 | |||
| Change in fair value of conversion option derivative liabilities | -3,987 | |||
| Total other non-operating loss (income) | -5,929 | |||
| Loss before provision for income taxes | -17,140 | |||
| Income tax benefit (expense) | -131 | |||
| Net loss | -17,009 | |||
| Basic (in dollars per share) | -0.15 | |||
| Basic (in shares) | 93,203,665 | |||
| Diluted (in dollars per share) | -0.15 | |||
| Diluted (in shares) | 93,203,665 | |||